NCT00849069View on ClinicalTrials.gov

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

PHASE1TerminatedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 12, 2009

Primary Completion Date

April 7, 2009

Study Completion Date

April 7, 2009

Conditions

Haemophilus InfluenzaeStreptococcus Pneumoniae

Interventions

BIOLOGICAL

GSK2231395A

3 doses intramuscular injections

BIOLOGICAL

TwinrixTM

3 doses intramuscular injections

Trial Locations (1)

B3K 6R8

GSK Investigational Site, Halifax

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY